No, I didn't buy yesterday to answer you but I may as the price is appealing here. However, I do not have much faith that Mark P will hit his third quarter enrollment target and Invivo's approach to the control arm debate will need to pass mustard with the FDA.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.